ImmunoGen Inc (IMGN.OQ) Key Developments | Reuters.com
Edition:
United States

ImmunoGen Inc (IMGN.OQ)

IMGN.OQ on NASDAQ Stock Exchange Global Select Market

3.18USD
28 Jun 2016
Change (% chg)

-- (--)
Prev Close
$3.18
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
500,435
52-wk High
$19.42
52-wk Low
$2.96

Latest Key Developments (Source: Significant Developments)

ImmunoGen announces pricing of $100 mln offering of Senior Notes
Wednesday, 15 Jun 2016 08:58am EDT 

Immunogen Inc : Sale of notes is expected to result in $96.7 million net proceeds to Immunogen . Interest will be payable semi-annually in arrears on january 1 and july 1 of each year, beginning january 1, 2017 . Sale of notes expected to result in proceeds of $111.2 million if initial purchasers exercise option to purchase additional notes in full . Notes will be senior unsecured obligations of Immunogen, and will bear interest at a rate of 4.50% per year .Immunogen announces pricing of $100 million offering of 4.50% convertible senior notes due 2021.  Full Article

Immunogen announces proposed $100 mln offering of convertible senior notes
Monday, 13 Jun 2016 04:01pm EDT 

Immunogen Inc : Immunogen announces proposed $100 million offering of convertible senior notes due 2021 . Says notes will be senior unsecured obligations of immunogen, and interest will be payable semi-annually .Immunogen Inc says intends to use net proceeds of offering for its operations, including but not limited to clinical trial expenditures.  Full Article

ImmunoGen reports positive early-stage data on ovarian cancer drug
Wednesday, 18 May 2016 05:01pm EDT 

Immunogen : Reports efficacy and safety data from a 46 patient cohort of mirvetuximab soravtansine in frα-positive ovarian cancer . Company preparing to meet with FDA in early 3q 2016; targeting initiation of phase 3 study in 4q2016 .Plan to have phase 3 testing of mirvetuximab soravtansine up and running by year end.  Full Article

ImmunoGen Inc Updates FY 2016 guidance
Friday, 29 Apr 2016 06:30am EDT 

ImmunoGen Inc:Updated its guidance for FY 2016.Expected FY 2016 revenues are now projected to be between $60 million and $70 million, compared with previous guidance of between $70 million and $80 million.Guidance for FY 2016 net loss is now expected to be between $135 million and $140 million, compared to its previous estimate of $120 million and $125 million with most of this change being non-cash related.  Full Article

ImmunoGen Inc Appoints Mark J. Enyedy as President and Chief Executive Officer
Tuesday, 26 Apr 2016 08:00am EDT 

ImmunoGen Inc:Mark J. Enyedy has been appointed President and CEO and elected to the Board of Directors, effective May 16.Enyedy succeeds Daniel Junius, who as previously announced is retiring from these positions and will continue to serve on ImmunoGen's Board.  Full Article

ImmunoGen and Merck establish collaboration for clinical evaluation of mirvetuximab soravtansine in combination with keytruda
Thursday, 4 Feb 2016 08:00am EST 

ImmunoGen Inc:Says the company and Merck have entered into a clinical research collaboration for the assessment of ImmunoGen's mirvetuximab soravtansine in combination with Merck's anti-PD-1 therapy.Says agreement is between immunogen and Merck, through a subsidiary.Says agreement includes a provision for potential expansion of the collaboration to include a subsequent phase 3 clinical trial.Additional details were not disclosed.  Full Article

ImmunoGen Inc gives FY 2016 guidance
Friday, 31 Jul 2015 06:30am EDT 

ImmunoGen Inc:Says that it expects FY 2016 revenues to be between $70 million and $80 million.Sees FY 2015 net loss to be between $120 million and $125 million.  Full Article

ImmunoGen Inc reaffirms FY 2015 net loss outlook, lowers revenue outlook
Friday, 24 Apr 2015 06:17am EDT 

ImmunoGen Inc:Continues to expect FY 2015 net loss between $60 and $65 million.Now expects FY 2015 revenues to be between $85 and $95 million, compared with previous guidance of between $100 and $105 million, due to changes in the expected timing of partner milestone events.  Full Article

ImmunoGen Inc and Hurricane LLC enters into royalty purchase agreement with Immunity Royalty Holdings - Form 8-K
Monday, 30 Mar 2015 08:02am EDT 

ImmunoGen Inc:Says company and its wholly owned subsidiary, Hurricane, LLC entered into a royalty purchase agreement with Immunity Royalty Holdings, L.P (purchaser)., which was formed by certain TPG Special Situations Partners’ investment funds.Transaction is subject to the satisfaction of customary closing conditions and is expected to close in early April.Purchase Agreement provides that, in consideration of the payment of $200 mln by the Purchaser to Hurricane.Purchaser will have the right to receive 100 pct of the royalty payments on commercial sales of Kadcyla (Kadcyla Royalties) arising under License Agreement with Genentech, Inc., as amended, until the Purchaser has received aggregate Kadcyla Royalties equal to $235 mln or $260 mln;.Depending on when the aggregate Kadcyla Royalties received by the Purchaser reach a specified milestone.Once the applicable threshold is met, if ever, we will thereafter receive 85 pct, and the Purchaser will receive 15 pct, of the Kadcyla Royalties for the remaining royalty term.  Full Article

Takeda Pharmaceutical announces business alliance with ImmunoGen
Monday, 23 Mar 2015 07:00pm EDT 

Takeda Pharmaceutical Co Ltd:Formed a business alliance of exclusive license of antibody-drug conjugate, which is owned by Takeda Pharmaceutical, with ImmunoGen Inc.  Full Article

BRIEF-ImmunoGen announces pricing of $100 mln offering of Senior Notes

* Sale of notes is expected to result in $96.7 million net proceeds to Immunogen